These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 30476367)

  • 1. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?
    Wroński J; Fiedor P
    J Clin Pharmacol; 2019 Apr; 59(4):445-462. PubMed ID: 30476367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study.
    Wroński J; Fiedor P; Głuszko P
    Int J Clin Pharm; 2019 Aug; 41(4):864-871. PubMed ID: 31172410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study.
    Kömel Pimenta PR; Ribeiro da Silva MR; Ribeiro Dos Santos JB; Kakehasi AM; Assis Acurcio F; Alvares-Teodoro J
    J Comp Eff Res; 2021 Apr; 10(6):509-517. PubMed ID: 33728937
    [No Abstract]   [Full Text] [Related]  

  • 6. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Necrosis Factor Inhibitor Dose Reduction for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Lawson DO; Eraso M; Mbuagbaw L; Joanes M; Aves T; Leenus A; Omar A; Inman RD
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):861-872. PubMed ID: 32166872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
    J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Bonovas S; Minozzi S; Lytras T; González-Lorenzo M; Pecoraro V; Colombo S; Polloni I; Moja L; Cinquini M; Marino V; Goletti D; Matucci A; Tocci G; Milano GM; Scarpa R; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):35-54. PubMed ID: 27924644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis.
    Hammoudeh M; Alarfaj A; Chen DY; Djoudi H; Youseif E; Zhu J
    Clin Rheumatol; 2013 Mar; 32(3):293-300. PubMed ID: 23242389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-α biologics: real-life results from a single-centre cross-sectional study.
    Uyaroglu OA; Seyhoglu E; Erden A; Kilic L; Karadag O; Akdogan A; Bilgen SA; Ertenli AI; Kiraz S; Kalyoncu U
    Rheumatol Int; 2020 Sep; 40(9):1501-1507. PubMed ID: 31993731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis.
    Tong Q; Cai Q; de Mooij T; Xu X; Dai S; Qu W; Zhao D
    PLoS One; 2015; 10(3):e0119897. PubMed ID: 25764452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.
    Apaydin H; Dogan I; Erten Ş
    Int J Rheum Dis; 2020 Mar; 23(3):454-456. PubMed ID: 31945270
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
    van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
    Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and productivity loss in patients with ankylosing spondylitis using tumor necrosis factor inhibitors.
    Ma KS; Kao PE; Chen KH; Liu CH
    Int J Rheum Dis; 2023 Jul; 26(7):1412-1413. PubMed ID: 36941023
    [No Abstract]   [Full Text] [Related]  

  • 17. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study.
    Uslu S; Gulle S; Sen G; Cefle A; Yilmaz S; Kocaer SB; Yuce Inel T; Koca SS; Yolbas S; Ozturk MA; Senel S; Inanc N; Dalkilic HE; Soysal Gunduz O; Tufan A; Akar S; Birlik AM; Sari I; Akkoc N; Onen F
    Sci Rep; 2024 Jun; 14(1):14194. PubMed ID: 38902436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.